# Iterative Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iterative-health

- Industry: Software
- Headquarters: Cambridge, US
- Website: www.iterativescopes.com
- Total disclosed funding: $271M
- Latest round: Series C (Apr 30, 2026)
- Investors on record: 14

## About

Based in the US, Iterative Scopes, Inc. specializes in transforming gastrointestinal (GI) care through innovative healthcare technology, leveraging AI solutions to enhance diagnostics and improve patient outcomes. Founded in 2017 and headquartered in Cambridge, US, Iterative Scopes, Inc. focuses on advancing gastrointestinal healthcare. The company is led by CEO Jonathan Ng. Iterative Health specializes in advanced healthcare technology and services aimed at transforming gastrointestinal (GI) care. The company’s core offerings include AI-powered solutions that optimize clinical trial processes, enhance diagnostics, and improve patient care. Their flagship product, SKOUT, provides real-time AI support for colorectal cancer screening and surveillance, empowering physicians to deliver timely interventions. Iterative Health serves a diverse client base, including clinical research sites, healthcare professionals, and life sciences organizations, primarily across the United States and Europe. By focusing on these geographical markets, the company aims to address pressing challenges in GI care and expand access to innovative therapeutics, ultimately improving patient outcomes. Iterative Health’s revenue model primarily revolves around partnerships and collaborations with clinical trial sponsors and research sites. This structure typically involves B2B transactions, where healthcare organizations utilize Iterative Health’s technology and services to enhance their research capabilities and patient care offerings. Clients benefit from subscription-based access to their unique products, including SKOUT, which facilitates efficient colorectal cancer screening and surveillance. While specific pricing plans for individual services are not publicly disclosed, the company’s focus on optimizing clinical trials and providing advanced diagnostics positions it to secure sustained revenue growth through ongoing partnerships with biopharmaceutical companies and research institutions. Iterative Scopes, Inc. plans to leverage recent funding to expand its product portfolio and enhance its presence in the healthcare market. The company is focused on developing new AI-driven solutions aimed at improving the efficiency of GI care. In April 2026, the company led by Intrepid Growth Partners and GV (Google Ventures), with participation from EDBI, a family office, Insight Partners and Obvious Ventures.

## Funding rounds

- Series C, Apr 30, 2026, $77M — Insight Partners, SG Growth Capital, GV, Obvious, Intrepid Growth Partners
- Series B, Dec 6, 2021, $150M — Insight Partners, Johnson & Johnson Innovation, Clearlake Capital Group, Eli Lilly & Company, Breyer Capital, Obvious
- Series A, Jul 23, 2021, $32M — Johnson & Johnson Innovation, Breyer Capital, Obvious, Lilly, Seae Ventures
- Seed, Jan 15, 2020, $7M — Wavemaker Partners, P5 Health Ventures, Tau Ventures
- Seed, Jun 15, 2019, $5.2M — Wavemaker Partners, P5 Health Ventures, TAU Ventures

## Investors

- Wavemaker Partners (https://capitalatlas.ai/funds/wavemaker-partners) — Seed
- P5 Health Ventures (https://capitalatlas.ai/funds/p5-health-ventures) — Seed
- TAU Ventures — Seed
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series A, Series B
- Obvious (https://capitalatlas.ai/funds/obvious) — Series A, Series B, Series C
- Lilly — Series A
- Seae Ventures (https://capitalatlas.ai/funds/seae-ventures) — Series A
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series B, Series C
- Clearlake Capital Group (https://capitalatlas.ai/funds/clearlake-capital-group) — Series B
- Eli Lilly & Company — Series B
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C
- GV (https://capitalatlas.ai/funds/gv) — Series C
- Intrepid Growth Partners (https://capitalatlas.ai/funds/intrepid-growth-partners) — Series C